Snowden Capital Advisors LLC Grows Position in Encompass Health Co. (NYSE:EHC)

Snowden Capital Advisors LLC grew its stake in shares of Encompass Health Co. (NYSE:EHC) by 6.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,307 shares of the company’s stock after purchasing an additional 500 shares during the period. Snowden Capital Advisors LLC’s holdings in Encompass Health were worth $767,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in EHC. T. Rowe Price Investment Management Inc. purchased a new stake in Encompass Health during the fourth quarter worth about $152,953,000. Norges Bank acquired a new stake in shares of Encompass Health during the 4th quarter valued at approximately $100,637,000. Raymond James Financial Inc. purchased a new stake in shares of Encompass Health during the 4th quarter worth approximately $77,944,000. Jennison Associates LLC acquired a new stake in shares of Encompass Health in the 4th quarter worth approximately $52,094,000. Finally, Farallon Capital Management LLC increased its stake in Encompass Health by 15,266.7% in the 4th quarter. Farallon Capital Management LLC now owns 461,000 shares of the company’s stock valued at $42,573,000 after purchasing an additional 458,000 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EHC. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, May 11th. Barclays raised their target price on shares of Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday, April 25th. KeyCorp upped their price target on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Royal Bank of Canada raised their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, April 28th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $120.86.

Encompass Health Stock Up 0.2%

Shares of NYSE EHC opened at $121.15 on Tuesday. The firm has a market cap of $12.21 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. Encompass Health Co. has a 1 year low of $82.74 and a 1 year high of $121.44. The firm’s 50 day moving average price is $105.97 and its 200 day moving average price is $100.90.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.12 earnings per share. As a group, sell-side analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.56%. Encompass Health’s payout ratio is currently 14.05%.

Insider Buying and Selling

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total transaction of $498,974.19. Following the completion of the sale, the insider now owns 11,958 shares of the company’s stock, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president now owns 79,710 shares of the company’s stock, valued at $9,149,910.90. This represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.